No change in calculated creatinine clearance after tenofovir initiation among Thai patients

Gayet-Ageron, Angèle; Ananworanich, Jintanat; Jupimai, Thidarat; Chetchotisakd, Ploenchan; Prasithsirikul, Wisit; Ubolyam, Sasiwimol; Braz, Michelle Le; Ruxrungtham, Kiat; Rooney, James F.; Hirschel, Bernard

doi:10.1093/jac/dkm064

Cited by 26 publications

(13 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, the TDF-related nephrotoxicity has hardly been evaluated in patients with small body weight, who are potentially at higher risk for larger drug exposure and thus, more severe toxicity [12]–[15]. Indeed, some recent studies including ours reported a higher incidence of TDF-related renal dysfunction among Asian patients with low body weight compared with previous studies on mostly Whites and African Americans with larger body weight [13], [16].…”

Section: Introductionmentioning

confidence: 66%

Renal Function Declines More in Tenofovir- than Abacavir-Based Antiretroviral Therapy in Low-Body Weight Treatment-Naïve Patients with HIV Infection

et al. 2012

View full text Add to dashboard Cite

ObjectiveTo compare the rate of decline of renal function in tenofovir- and abacavir-based antiretroviral therapy (ART) in low-body weight treatment-naïve patients with HIV infection.DesignWe conducted a single-center retrospective cohort study of 503 Japanese patients who commenced on either tenofovir- or abacavir-based initial ART.MethodsThe incidence of renal dysfunction, defined as more than 25% fall in estimated glomerular filtration rate (eGFR) from the baseline, was determined in each group. The effect of tenofovir on renal dysfunction was estimated by univariate and multivariate Cox hazards models as the primary exposure. Changes in eGFR until 96 weeks were estimated in both groups with a repeated measures mixed model.ResultsThe median body weight of the cohort was 64 kg. The estimated incidence of renal dysfunction in the tenofovir and the abacavir arm was 9.84 per 100 and 4.55 per 100 person-years, respectively. Tenofovir was significantly associated with renal dysfunction by univariate and multivariate analysis (HR = 1.747; 95% CI, 1.152–2.648; p = 0.009) (adjusted HR = 2.080; 95% CI, 1.339–3.232; p<0.001). In subgroup analysis of the patients stratified by intertertile baseline body weight, the effect of tenofovir on renal dysfunction was more evident in patients with lower baseline body weight by multivariate analysis (≤60 kg: adjusted HR = 2.771; 95%CI, 1.494–5.139; p = 0.001) (61–68 kg: adjusted HR = 1.908; 95%CI, 0.764–4.768; p = 0.167) (>68 kg: adjusted HR = 0.997; 95%CI, 0.318–3.121; p = 0.995). The fall in eGFR was significantly greater in the tenofovir arm than the abacavir arm after starting ART (p = 0.003).ConclusionThe incidence of renal dysfunction in low body weight patients treated with tenofovir was twice as high as those treated with abacavir. Close monitoring of renal function is recommended for patients with small body weight especially those with baseline body weight <60 kg treated with tenofovir.

show abstract

Section: Introductionmentioning

confidence: 66%

Renal Function Declines More in Tenofovir- than Abacavir-Based Antiretroviral Therapy in Low-Body Weight Treatment-Naïve Patients with HIV Infection

et al. 2012

View full text Add to dashboard Cite

show abstract

“…Indeed tenofovir molecule is controversial in numbers of studies. Someone had found that the use of long-term tenofovir resulted in a net decrease of glomerular flow filtration [26,27]; by against other showed a good renal safety of tenofovir [28][29][30]. Overall, it seems that tenofovir is not nephrotoxic in the long term at least when it is prescribed in patients without renal impairment [31].…”

Section: Prevalence Of Chronic Kidney Failure In People With Hivmentioning

confidence: 99%

Prevalence of Chronic Kidney Failure and Associated Factors in Patients Treated by Antiretroviral in the National Teaching Hospital of Cotonou

Dm¹,

Vigan²,

Azon-Kouanou³

et al. 2015

J Nephrol Ther

View full text Add to dashboard Cite

“…Some cohort studies described no significant evidence of renal dysfunction with the use of TDF [15][16][17] in contrast to the other study. 9 Most of HIV-infected patients' care in Thailand, where is a resource-limited setting, is covered by the National AIDS Program.…”

Section: Introductionmentioning

confidence: 74%

“…Median (IQR) time to renal function decline was 8 (3-13.5), 11 (6)(7)(8)(9)(10)(11)(12)(13)(14)(15)(16)(17)(18), and 11 (6-19) months, respectively, when estimated from the total number of the patients. By Kaplan-Meier analysis, median time to renal function decline was 28 (95% CI 25-30) months for eGFR criteria and 31 (95% CI 28-34) months for CCrCl criteria.…”

Section: Resultsmentioning

confidence: 99%

Monitoring of Renal Function among HIV-Infected Patients Receiving Tenofovir in a Resource-Limited Setting

Kiertiburanakul

Chaisiri

Kasettratat

et al. 2011

Journal of the International Association of Physicians in AIDS

View full text Add to dashboard Cite

The use of tenofovir disoproxil fumarate (TDF) is supposed to be increased in a resource-limited setting due to the changing of the guidelines. TDF-associated renal function declines among HIV-infected patients were defined by an increase of serum creatinine (SCr) >1.5 times, a 25% decrease in calculated creatinine clearance (CCrCl), or an estimated glomerular filtration rate (eGFR) from the baseline. Of all, 99% were antiretroviral treatment (ART)-experienced patients. At the 30th month, 19 (5.3%), 53 (14.9%), and 63 (17.7%) patients had renal function decline as defined by the above criteria with an incidence of 4.5, 12.5, and 14.6/100 person-year. A proportion of patients with a renal function decline detected by CCrCl or eGFR criteria was not different (P ¼ .301), whereas, it differed from that detected by SCr criteria (P < .001). In conclusion, we encourage either CCrCl or eGFR calculations in monitoring renal function decline among HIV-infected patients receiving TDF in resource-limited settings.

show abstract

No change in calculated creatinine clearance after tenofovir initiation among Thai patients

Abstract: We did not find renal dysfunction on tenofovir among Thai patients included in the Staccato trial. Tenofovir could be safely prescribed at a standard dosage of 300 mg once daily in the Thai population.

Cited by 26 publications

References 13 publications

Renal Function Declines More in Tenofovir- than Abacavir-Based Antiretroviral Therapy in Low-Body Weight Treatment-Naïve Patients with HIV Infection

Renal Function Declines More in Tenofovir- than Abacavir-Based Antiretroviral Therapy in Low-Body Weight Treatment-Naïve Patients with HIV Infection

Prevalence of Chronic Kidney Failure and Associated Factors in Patients Treated by Antiretroviral in the National Teaching Hospital of Cotonou

Monitoring of Renal Function among HIV-Infected Patients Receiving Tenofovir in a Resource-Limited Setting

Contact Info

Product

Resources

About